Skip to main content
Premium Trial:

Request an Annual Quote

Bayer Diagnostics, Innogenetics

Premium
Bayer Diagnostics and Innogenetics have launched their jointly developed Versant HCV Genotype 2.0 assay for hepatitis C virus genotyping. The assay is an upgrade of Bayer’s Versant HCV Genotype 1.0 Assay and is now available for sale in Europe.
 
In addition to its ability to accurately classify HCV genotypes 1 to 6, the assay now also provides “accurate identification of genotypes 6c-l (formerly known as genotypes 7, 8, and 9) and improves the identification of genotype 1a and 1b,” the companies said in a statement.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.